{"id":"W4417421081","doi":"10.3390/ph18121898","title":"First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours","year":2025,"lang":"en","type":"article","venue":"Pharmaceuticals","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre; SignalChem (Canada)","funders":"","keywords":"Pharmacokinetics; Clinical trial; Adverse effect; Bioavailability; Drug; Tolerability; Phases of clinical research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000474081,0.0001609269,0.0005192495,0.0001945208,0.0000660224,0.000006855933,0.0001019176,0.0001605573,0.00003156471],"category_scores_gemma":[0.0001688956,0.000137042,0.0000593247,0.0002794806,0.0002553612,0.0001235478,0.00007155009,0.0003549142,0.000003504933],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005495399,"about_ca_system_score_gemma":0.000074261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001560613,"about_ca_topic_score_gemma":0.00002266865,"domain_scores_codex":[0.9984317,0.0002001325,0.0007070537,0.0003252903,0.00004563125,0.0002901915],"domain_scores_gemma":[0.9992836,0.0003002686,0.0001612887,0.0001459647,0.00008296227,0.00002597981],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2013863,0.024593,0.3781684,0.0001931176,0.0006291108,0.000004359321,0.0007972743,0.0001009544,0.3421717,0.002039537,0.0004826693,0.04943348],"study_design_scores_gemma":[0.4392435,0.003083453,0.3498894,0.0003276724,0.0001406572,0.000001478089,0.00005783612,0.0001576151,0.2038624,0.0002265608,0.002712884,0.0002964527],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975861,0.0006414525,0.00007203123,0.0001539151,0.0003247973,0.0009144538,0.00002000588,0.00001524695,0.0002720365],"genre_scores_gemma":[0.9995991,0.00007886753,0.00004758642,0.0001003706,0.00001556832,0.00004783711,0.00003611119,0.000009708506,0.0000648715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2378572,"threshold_uncertainty_score":0.5588409,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03782600799213566,"score_gpt":0.4090290512616684,"score_spread":0.3712030432695327,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}